Eli Lilly to invest $3bn in Wisconsin facility expansion
Eli Lilly has announced a $3bn investment to expand its newly acquired manufacturing facility in Kenosha County, Wisconsin, US, which…
All articles by
-
-
Muna-GSK alliance to fast-track Alzheimer’s disease treatments
Muna Therapeutics has entered a research alliance with GSK to expedite Alzheimer's disease treatments by discovering and validating new drug…
-
FDA ARMAT status for Affimed and Artiva’s lymphoma combo therapy
The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Affimed and Artiva Biotherapeutics’…
-
Dewpoint Therapeutics and Mitsubishi Tanabe link on ALS treatment
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered a strategic research partnership focusing on the development of the…
-
LEO Pharma’s eczema cream gains MHRA marketing authorisation
LEO Pharma has gained marketing authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus…
-
FDA approves AstraZeneca’s Imfinzi to treat LS-SCLC
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to treat limited-stage small cell…
-
Maze Therapeutics raises $115m to advance kidney disease candidates
Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829…
-
Ipsen and Biomunex enter agreement for cancer therapy
Ipsen has entered an exclusive worldwide licensing agreement with Biomunex Pharmaceuticals for BMX-502, a first-in-class bispecific antibody designed to engage…
-
Takeda licensed for anaemia therapy by Keros Therapeutics
Takeda has agreed to receive an exclusive global licence from Keros Therapeutics to advance the development, manufacture and commercialisation of…
-
Lundbeck acquires all outstanding shares of Longboard Pharma
Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster its capabilities in the neuro-rare disease…